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The ability to culture complex organs is currently an important goal in biomedical research. It 
is possible to grow organoids (3D organ-like structures)in vitro; however, a major limitation 
of organoids, and other 3D culturesystems, is the lack of a vascular network. Protocols 
developed for establishing in vitro vascular networks typically use human or rodent cells. A 
major technical challenge is the culture of functional (perfused) networks. In this rapidly 
advancing field, some microfluidic devices are now getting close to the goal of an artificially 
perfused vascular network. Another development is the emergence of the zebrafish as a 
complementary model to mammals. In this review, we discuss the culture of endothelial 
cells and vascular networks from mammalian cells, and examine the prospects for using 
zebrafish cells for this objective. We also look into the future and consider how vascular 
networks in vitro might be successfully perfused using microfluidic technology.  
 






In multicellular animals, nutrients and oxygen are carried by the cardiovascular system, and 
diffuse directly into the tissues[1]. Similarly, waste products are removed from the tissues by 
the same system. This allows the tissues to grow and develop into functional organs[1]. The 
cells in a living tissue are within 100-200 µm range of a blood capillary[2]. This is important 
for the survival of the cells as the oxygen and nutrients cannot diffuse through the tissue 
beyond this range [3].A blood supply (vasculature connected to a pump) has therefore 
evolved to overcome the constraint on growth imposed by limited diffusion.  
One area where blood vessel development is relevant is tissue engineering for regenerative 
medicine and organ transplantation [4]. Currently, the lack of vascularization of tissues in 
vitro is a major hurdle in reaching this objective [5, 6]. This is unfortunate because cultured, 
vascularized tissues could not only have clinical applications [4], but could also be used as an 
alternative to whole animal models in research [7]. There are currently great efforts directed 
towards growing cells and tissues from a patient’s own body (autologous transplantation), in 
order to overcome the potential danger of allogenic (from another individual) graft 
rejection, and graft-versus-host reactions[8, 9].  
With current tissue culture techniques, tissues cannot be grown more than 100-200 µm in 
thickness, primarily because of the limited diffusion of nutrients and oxygen [10]. Tumor 
cells grown in non-adherent culture can develop into spherical masses (spheroids) up to 
3mm in diameter, typically with a core of cells that are dead or dying due to diffusion 
limitation [11]. Similarly, masses of normal (non-malignant) cells grown in vitro are called 
organoids, and are currently the focus of great interest in biomedical research because they 
show some organization of tissues resembling in vivo organs[12]. We believe that the 
development of anin vitro vascular network could improve the culturing of spheroids and 
organoids (Figure 1) by allowing the tissues to grow and function in a way that is closer to 
the in vivosituation [13].  
Other applications ofvascular network culture could be fundamental studies of vascular 
development[14];recapitulating disease conditions such as the retinal microvascular 
abnormalities seen in diabetes[15]or the abnormal angiogenesis in tumor development[16]; 
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testing anti-angiogenic compounds in cancer research [17] or candidate drugs for their safe 
clinical application [18]; and studies in vascular regenerative medicine [19] (Figure 1). 
 
Figure 1: Potential applications of a vascular network culture. 
 
It has long been known from the field of human and animal surgery, including transplant 
surgery, that tissue can become re-vascularized when grafted to a suitable site[20, 21]. 
Similarly, developmental studies have shown that embryonic tissues can also readily become 
re-vascularized, and continue to grow into functional organs, when transplanted to various 
locations in the embryo[22].Furthermore, embryonic organ primordia can become 
vascularized if transplanted not only to the embryo itself, but to the vascular network in the 
extra-embryonic membranes. A good example of this is the chicken embryo chorioallantoic 
membrane (CAM) system[23, 24]. In that model, organ primordia are placed onto the highly 
vascular CAM, the blood vessels first having been scratched to open them up. The organ 
primordia can then form a vascular connection with the CAM vessels, and undergo 
reasonable growth and morphogenesis. The CAM, however, is highly sensitive to 
environmental factors [25], therefore the development of the tissue graft is not perfect, 
possibly because it is not submerged in a supporting volume of fluid, but rather is exposed to 
in vitro vascular network 






the air. In a sense, therefore, the CAM and other developmental systems show that the 
growth of organs on vascular beds is a possibility. What is needed, however, is a vascular 
bed ex vivo that is perfused by some kind of microfluidic system. 
Most of the current research describing vasculogenesis (de novo formation of blood vessels 
from progenitor cells)and angiogenesis (formation of blood vessels from existing blood 
vessels) uses mammalian models, mainly mice. However, these models are fairly expensive, 
time consumingand require ethical and other permissions[26]. Endothelial cell lines such as 
human umbilical vein endothelial cells (HUVECs) are commonly used for developing in vitro 
vascular networks[27].Other sources for developing such cultures include embryonic or adult 
stem cells or tissue explants. The uses and limitations of these techniques are discussed in 
detail in the following sections. 
Zebrafish can be an alternative to mammalian models for studying vascular 
development[28].The zebrafish produce a large number of fertilized eggs at low cost; the 
embryos are externally fertilized and therefore readily accessiblefor experiments[29].In 
some jurisdictions, zebrafish embryos have fewer ethical restrictions. For example, in the 
European Union, the Directive 2010/63/EU on the protection of experimental animals allows 
zebrafish embryos to be used until 5 days post fertilization (dpf)without 
restriction[30].Finally, the zebrafish genome has been sequenced and there is a high level of 
conservation between zebrafish and human protein coding genes [31]. This similarity 
supports the use of zebrafish to model various human diseases [32, 33].Because of these 
advantages, the zebrafish is currently emerging as a model species to study vasculogenesis 
and angiogenesisin vivo[28]. Transgenic reporter lines are proving very useful in these 
studies [28].  
In this review we give a general overview of vascular development in vivo and the role of 
various factors in the development of vasculature.Then, we review the current procedures 
used to culture vascular networks using mammalian endothelial cells and tissue explants. 
Then,we review the use of zebrafish to study various aspects of vasculogenesis and 
angiogenesis in vivo. We look forward by summarizing the potential use of zebrafish model 
for in vitro studies of vascular development.Organoids (organ-like structuresin vitro, lacking a 
vascular network) which have a limited ability to undergo organogenesis, are discussed in 
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the next section. Finally, we summarize studies that use microfluidic technology to develop 
perfusable vascular networks, and we discuss their potential in the field of tissue 
engineering. 
2. Development of vasculaturein vivo 
Formation of a vascular system is an essential process in embryonic development. Because 
multicellular tissues cannot survive without a blood supply, the cardiovascular system is one 
of the earliest systems formed during embryogenesis[34, 35]. The endothelial precursor cells 
(angioblasts) differentiate into endothelial cells and undergo the process of vasculogenesis 
in early embryos to form the primitive blood vessels [36].Studies on zebrafish have shown 
thatthe angioblasts appear in the lateral mesoderm, migrate to the midline of the embryo 
and form the first blood vessels [37]. In adult mice and humans,endothelial progenitor cells 
reside in the bone marrow asmultipotent adult progenitor cells, and contribute to the 
formation of new blood vessels [38]. 
Further development of blood vessels takes place by the extension of the pre-
existingvascular network through the process ofsprouting and non-sprouting angiogenesis 
[39].During angiogenic sprouting, some endothelial cells within the existing blood vessel are 
selected as tip cells, and migrate in the direction of angiogenic stimuli[40]. The surrounding 
extracellular matrix is degraded by specific proteases released during the process [41]. 
Meanwhile, the stalk cells (endothelial cells following the tip cells) proliferate to extend the 
blood vessel[40]. Further in development the vascular network also extends through 
intussusceptive or non-sprouting angiogenesis [42]. The mature blood vessels attain arterial, 
venous and lymphatic differentiation types having different structures and functions [43]. 
Endothelial differentiation and blood vessel formation is a complex process which requires a 
number of growth factors, cell types and extracellular matrix (ECM) components, discussed 
in the following section. 
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3. Factors controlling vasculogenesis and angiogenesisin vivo 
3.1. Protein factors influencing vascular development 
The differentiation of endothelial cells and the formation of blood vessels is mainly 
controlled by several protein factors[44].Important protein factors in this context are 
summarized inTable 1. Some of these factors are released by the endothelial cells 
themselves, other factors are stabilizing signals released by other cell types[44]. The 
differentiation of angioblasts is induced mainly by fibroblast growth factor 2 (FGF-2) and 
bone morphogenic protein-4 (BMP-4) [43]. FGF-2inducesthe expression of vascular 
endothelial growth factor (VEGF) and other important chemokines required to control 
vascular morphogenesis[45]. The importance of FGF-2 for vascular formation has been 
shown in studies on quail and zebrafish embryos [46, 47].Similarly, BMP-4 deficiency is 
associated with severe abnormalities in early mouse embryos, including the lack of a well-
organized vasculature [48]. 
Among the endothelial growth factors, VEGFs play the predominant role in regulating the 
formation of blood vessels [49]. The VEGF family consists of several VEGF genes of which 
VEGF-A, which interacts with endothelial cells through VEGF receptor 2 (VEGFR2 also known 
as KDR or FLK1), is the main component responsible for the viability and proliferation of 
endothelial cells [50]. The VEGF mRNA is alternatively spliced resulting in four different 
isoforms of VEGF (VEGF121, VEGF165, VEGF189, VEGF206), denoted by the number of amino 
acids in their peptide chain[51]. These isoforms, having different rates of diffusion in the 
ECM due to differences in their heparin binding ability, generate a gradient, producing 
chemical signals for the directional migration of newly forming capillaries [52].VEGFs also 
have important roles in the differentiation, migration and cell-cell adhesion of endothelial 
cells, as well asstimulating sprouting angiogenesis and the activationof tip cells[53]. 
Placental growth factor (PlGF), a member of VEGF family expressed in the placenta of early 
mammalian embryos,has a role in the activation of VEGFR2 and establishing interaction 
between VEGF-A and VEGFR2 [54]. PlGFhas been demonstrated to increase the angiogenic 
potential of VEGF in ischemic myocardium in mouse [55]. PlGFexpression is normally low in 




Table 1. Description and role of different proteins involved in vascular development. 








VEGF-A: endothelial cellsurvival factor, main 
regulator of vascular development; VEGF-





Embryonic vascular development, pathological 
angiogenesis 
[54] 
PDGF-B Endothelial cells Vessel maturation;binds to PDGF receptor-β on 
pericytes 
[49] 
FGF-2 Multiple cell 
types 
Differentiation of angioblasts; stimulation of 
VEGF expression; maintenance of vascular 
integrity  
[43, 45] 
Ang-1 Mural cells Maintenance of endothelial cell quiescence; 
stabilization of vessel walls  
[44, 49] 
Ang-2 Angiogenic tip 
cells 
Acts as antagonist of Ang-1; promotes 
endothelial cell proliferation 
[44, 49] 
TGF-β Endothelial and 
mesenchymal 
cells 
Embryonic vascular development; induces 
vascular smooth muscle cell differentiation 
[57, 58] 
BMP-4 Mesoderm  Differentiation of angioblasts; induction of VEGF 
expression 
[43, 59] 
 Egfl-7 Endothelial cells Facilitates tube formation by coordinating 









VEGFR1 and R2 bind to VEGF-A, B and PlGF. 
VEGFR2 is the main mediator of angiogenesis. R3 




Endothelial cells Specification of arteries and veins [43, 44] 
VE-
cadherin 
Endothelial cells Maintenance of endothelial cell-cell contact and 
inhibition of endothelial proliferation 
[61] 
Dll-4 Endothelial tip 
cells 







Restricts formation of endothelial tip-cell in 
response to Dll-4, ensures directional sprouting 
[62] 
Abbreviations: Ang, angiopoietin; BMP, bone morphogenetic protein; Dll, delta like ligand; FGF, fibroblast 
growth factor; PDGF,platelet-derived growth factor; PlGF, placental growth factor; TGF-β, transforming 
growth factor β; VE-cadherin, vascular endothelial cadherin; VEGF, vascular endothelial growth factor; VEGFR, 
vascular endothelial growth factor receptor. 
 
Other growth factors involved in the spreading and maturation of blood vessels include 
angiopoietins (Ang-1 and Ang-2)[63], platelet-derived growth factor-B (PDGF-B) [64] and 
transforming growth factor β (TGF-β) [65], reviewed in Refs. [44, 49]. Epidermal growth 
factor (EGF)-like domain-7 is also secreted by endothelial cells, which facilitatesthe 
formation of vascular tubes[60].Many other transcription factors and signalling molecules 
have been identified to be involved in the differentiation of endothelial cells and the 
regulation of vascular development reviewed in Ref.[66].In response to low oxygen levels in 
the tissues, Hypoxia inducible factors (HIFs) regulates the expression of a number of pro-
angiogenic factors including VEGF, PlGF, Ang-1, Ang-2 and PDGF-B[67]. The HIFs are 
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considered to be the principle mediators of in vivo vasculogenesis and angiogenesis at all 
developmental stages[67]. 
In addition to the secreted protein factors, membrane proteins on the surface of endothelial 
cells also play an important role in vascular morphogenesis (Table 1). Examples of these 
membrane proteins include vascular endothelial cadherin (VE-cadherin), which functions to 
maintain endothelial cell-cell contact during VEGF-induced migration[61];and delta like 
ligand-4 and Notch-1, which specifythe endothelial tipvs. stalk cells during sprouting 
angiogenesis[62]. 
3.2. Role of other cell types in vascular development 
In addition to the secreted and membrane-bound protein factors discussed above, cell types 
other than endothelial cells also contribute to the formation of blood vessels. Pericytes and 
smooth muscle cells promote the proliferation and survival of endothelial cells and provide 
structural support to the blood vessels [68, 69]. Pericytes possess a number of receptors 
specific for the binding of angiogenic growth factors (such as PDGF-B and TGF-β) released by 
endothelial cells[70]. Similarly, the receptor for Ang-1 (a growth factor released by pericytes 
and other mural cells) is expressed on endothelial cells. This interaction between pericytes 
and endothelial cells contributes to angiogenic sprouting, vessel maturation and 
maintenance[70]. In the blood vessels of the central nervous system, pericytes have been 
reported to express tight and adherens junction proteins, thus regulating the permeability of 
blood-brain barrier [71]. 
Macrophagesare reported to be involved in connecting two blood vessel sprouts in the 
process called anastomosis [72]. A similar function is performed by microglial cells in the 
central nervous system, promoting the development of a complex vascular network [73]. 
Under certain conditions (e.g. hypoxia), the parenchymal cells (neurons, hepatocytes, 
myocytes etc.) release angiogenic growth factors to initiate sprouting angiogenesis 
[74].Platelets have been shown to contain isolated granules with stored pro- or anti-
angiogenic factors[75]. These granules are released selectively upon distinct stimulation 
pathways, favouring or hinderingangiogenesis [76]. Similarly, adipose stromal cells(a 
population of adult stem cells residing in fat tissue) release growth factors (such as VEGF, 
TGF-β and FGF) under ischemic conditions, promoting angiogenesis[77]. 
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3.3. Role of extracellular matrix 
Extracellular matrix (ECM)contributes to the formation and diversity of blood vessels in 
several ways including: (i) maintaining the histological structure and elasticity of the vessels, 
(ii)regulating the proliferation and differentiation of endothelial cells, and (iii) transporting, 
modifying or blocking the angiogenic growth factors[78].The ECM is a complex network of 
macromolecules and its composition and properties are highly variable among different 
tissues, affecting the tissue-specific differentiation of stem cells [79]. The protein 
components of ECM interact specifically with the transmembrane protein integrinswhich 
activate signalling pathways inside the cells,resulting in expression of particular genes that 
influence cellular differentiation [80].The biophysical properties of ECM (stiffness, elasticity 
etc.) are also thought to induce cellular pathways (collectively known as 
mechanotransduction pathways) affecting cell behaviour and fate [81]. 
Endothelial cells synthesize their own ECM, the major components of which typically include 
collagen type-IV, nidogens, heparansulfate proteoglycans and laminins [82]. Research on the 
ECM of blood vessels have shown the presence of different ECM components at different 
stages of vascular development [83]. In the beginning of the process, the endothelial cells 
adhere to and migrate on a laminin-rich ECM which is later replaced by a collagen type-I rich 
ECM to support vascular tube formation [83]. Another layer of ECM in the wall of blood 
vessels (the medial layer or tunica media) is synthesized by smooth muscle cells and includes 
fibrillin microfibrils, collagens and elastin as major components [84].Large vessels have an 
outer adventitial layer of ECM, containing fibronectin, fibrillar collagen and other proteins 
[84].The ECM of actively growing blood vessels also contains higher levels of fibronectin and 
its distinct splice isoforms, compared to the ECM of quiescent vessels [85].At sites of injury, 
platelets secrete fibrinogen which coagulates into a fibrin clot providing a substrate for 
wound healing [86]. 
The effect of collagen type-I, fibrin [87], collagen type-IV [88], fibronectin [89] and laminin 
[90] on vascular development in vitro has also been demonstrated. Matrigel® contains 
Engelbreth-Holm-Swarm tumor-derived ECM and has been used for various in vitro and in 
vivo angiogenesis assays [91].The composition of Matrigel® includes collagen type-IV, 
laminin, entactin and heparansulfate proteoglycan as well as growth factors such as FGF, 
PDGF, EGF and TGF-β [91]. In addition to these naturally-derived ECM components, synthetic 
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biopolymers (such as polyethylene glycol and poly-D-lysine) have also been proven to 
enhance vasculogenesis and angiogenesis in vitro [92, 93]. 
3.4. Haemodynamic factors 
Shear stress generated by blood flow on the luminal surface of endothelial cells is a 
mechanical factor that induces intracellular biochemical pathways resulting in gene 
expression changes and the modulation of the structure and function of blood vessels [94]. 
Heparin binding EGF-like growth factor is one such factor which is expressed in response to 
reduced blood flow and induces vessel narrowing [95]. Other molecular pathways involved 
in vascular remodelling are reported to be regulated by changes in shear stress leading to 
the expression of PlGF [96], Notch-1 [97], and Smad6 (involved in TGB-β signalling) proteins 
[98]. 
Microfluidic culture of endothelial cells is currently an emerging technology which mimics 
the physiological shear stress on cultured cells to achieve the goal of culturing functional 
blood vessels for tissue engineering [13, 99]. A number of techniques for culturing vascular 
networks have been described in which endothelial growth factors, ECM components and 
microfluidics are combined (see following sections for detailed discussion);however, the 
development of fully functional blood vessels still remains a challenge [99]. 
4. Culture of vascular networks using endothelial cells 
Pure endothelial cell populations can develop into vascular network-like structures in culture 
[27]. However, these networks are not sufficiently robust to be used for tissue engineering; 
they are mainly used to screen pro- and anti-angiogenic compounds for activity. Pure 
endothelial cell populations are derived from various sources including embryonic stem cells, 
induced pluripotent stem cells and adult tissues (Figure 2; [100]). Human macro- and micro-
vascular endothelial cells are commercially available [101-104]and have the ability to form 
vascular networks in vitro. The most commonly used endothelial cells in this regard are the 
HUVECs [27, 90, 105-110], derived from the veins of the umbilical cord (Table 2). Other 
endothelial cell types such as bovine aortic endothelial cells [111] and rat aortic endothelial 






Figure 2. Schematic overview of three possible approaches to establishing cultures 
of vascular networks. Stem cells, depending on their source, could be embryonic 
stem cells, mesenchymal stem cells, or induced pluripotent cells. Endothelial cells are 
in blue; diverse supporting cells are represented schematically by red and yellow.  
 
By contrast, the culture of well-defined vascular networks with a lumen requires the co-
culture of multiple cell types with endothelial cells [100]. The important supporting cell 
types,known to induce network formation by endothelial cells, include pericytes[113], 
animal or human embryos or adult tissues 
stem cells organ explant 
cell differentiation 
pure endothelial cells 
vascular sprouting 
co-culture 
vascular network formation in extracellular matrix 
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mesenchymal stem cells [109], fibroblasts [107], hepatocytes [114], smooth muscle 
cells[115] and adipose-derived stem cells (ASCs) [106]. The importance of fibroblasts in 
enhancing angiogenesis has been shown in co-culture with HUVECs[107, 116]. Growth 
factors derived from fibroblast cultures in conditioned medium have also been shown to 
increase vascular morphogenesis and vessel stability from HUVECs in 3D fibrin 
gels[108].Furthermore, the ECM components and angiogenic growth factors secreted by 
fibroblasts have been found to be critical for vascular tube formation from HUVECs[117].  
The culture of vascular networks is established in naturally-derived matrices (such as 
Matrigel® [116], collagen type-I [118] and fibrin [106]); as well as in synthetic matrices ( such 
as Puramatix™ [87] and polyethylene glycol hydrogel [119]) both of which types mimic 
native ECM. These matrices are particularly valuable for promoting successful vascular 
morphogenesis in vitro [92]. For a vascular network formation, the endothelial cells may be 
cultured on a 2D surface coated with one or a combination of these gel matrices; or in a 3D 
gel matrix (Table 2). In one study with HUVECs, increasing the thickness of Matrigel®was 
shown to increase the mean vascular cord length, and to decrease the network density 
[119].Combinations of different gel components can be used to mimic the complexity of 
natural ECM. The addition of laminin to collagen type-I scaffoldshas been shown to increase 
network formation and VEGFR2 expression by HUVECs in culture[90]. Similarly, increased 
network formation from HUVECs was observed in composite collagen type-I/fibrin matrix 
compared to pure collagen [110]. 
Studies in which vascular networks are cultured from endothelial cells have revealed the 
important role of several cellular and molecular factors. In one study, ASCs were found to 
enhance vascular network formation from HUVECs in 3D fibrin gels [106]. That study showed 
that the expression of angiogenesis related genes (VE-cadherin, VEGFR2) and proteins 
(VEGF, FGF, Ang-1) was higher in ASCs/HUVECs co-culture compared to pure HUVECs culture 
[106]. ASCs have also been shown to be critical for vascular network formation from blood 
vascular and lymphatic endothelial cells [120].Studies on human dermal microvascular 
endothelial cells have revealed the role of VEGF in specialization of the tip endothelial cells 
and their directional migration to form capillary-like structures [121]. Similarly, inducing the 
Notch signalling pathway upregulated VEGF-A, VEGF-B and VEGF-R1 expressions, and 
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promoted vascular network formation in co-cultured mouse brain microvascular endothelial 
cells and ASCs in 3D collagen type-I gel [122]. 









Main outcomes Possible 
applications 
Ref. 
HUVEC 2D BME EGM-2 Vascular network formation. Drug screening [27] 
HUVEC 
HBMSC 




Laminin and HBMSCs 





HUVEC 2D Matrigel® RPMI 1640 The anti-angiogenic effect of 
WIF-1 was reversed by 
hypoxic conditions. 
Cancer research [105] 
HUVEC 
ASC 
3D Fibrin EGM-2 Vasculogenesis was more 







2D  M199, 
ECGS, CS 
HDF co-culture and bio-




















3D Col-1 + Fbn DMEM/F12, 
VEGF, bFGF, 
HGF 


















BAEC 2D  Matrigel® DMEM,  
VEGF, rGAL-
8 
GAL-8 promoted endothelial 
cell migration and capillary 
formation. 
Cancer research [111] 




vascular formation in vitro. 





EGM-2 Pericytes enhanced network 






3D Fibrin  M199 Co-culture with SMCs 
increased length and density 







2D Matrigel® EGM-2 Capillary-like network 









2D Col-1 EBM-2 Revealed Collagen binding 
to specific integrin on 
endothelial cells activating 








Matrix thickness and 
stiffness affected vascular 









Fibrin  EGM-2, 
VEGF-C 
BEC and LEC formed 

















Abbreviations: Ang-1, angiopoietin-1; ASC, adipose-derived stem cells; BAEC, bovine aortic endothelial cells; 
BEC, blood vascular endothelial cells; CC-SMC, canine carotid artery-derived smooth muscle cells; CJ-EC, canine 
jugular vein-derived endothelial cells; bFGF, basic fibroblast growth factor; BME, basement membrane extract 
(Trevigen); Col-1, collagen type-I; CS, calcium silicate; DMEM, Dulbecco’s modified Eagle’s medium; EBM, 
endothelial basal medium; ECGS, endothelial cell growth supplement (Promocell); ECM, extracellular matrix; 
EGM, endothelial growth medium; EVCs, early vascular cells;F12, Ham’s F-12 medium; Fbn, fibronectin; HA-
hydrogel, hyaluronic acid based hydrogel; HBMSC, human bone marrow-derived mesenchymal stem cells; HDF, 
human dermal fibroblasts; hES-MC, human embryonic stem cell derived mesenchymal cells; HGF, hepatocyte 
growth factor; HMVEC, human dermal microvascular endothelial cells;HUVEC, human umbilical vein 
endothelial cells; LEC, lymphatic endothelial cells;M199, medium 199 (Lonza); MSC, mesenchymal stem cells; 
NHLF, human normal lung fibroblasts; PEG, polyethylene glycol hydrogel;RAEC, rat aortic endothelial cells; 
RBMVEC, rat brain microvascular endothelial cells;rGAL8, recombinant galectin-8; RPMI, Roswell Park 
Memorial Institute medium (Gibco); SF, skin fibroblasts; TGF-β, transforming growth factor beta; VEGF, vascular 
endothelial growth factor; WIF-1, Wnt inhibitory factor-1. 
 
4.1. Limitations of endothelial cell culture 
Endothelial cell cultures are relatively easy to maintain. However, there are certain 
limitations which need to be considered while carrying out endothelial culture. A blood 
vascular network constitutes a number of vessel types, from large vessels to micro vessels, 
and each vessel type has its own unique properties (including endothelial cell subtypes). 
Therefore it is challenging to attempt to recapitulate the formation of different vessel types 
using a homogeneous endothelial cell population [123]. Primary endothelial cell cultures are 
usually derived from terminally differentiated tissues; these cells have limited proliferative 
and regenerative capacity, and a short life span in vitro [124, 125].  
Endothelial cells derived from different sites within the same tissue express different genes 
and respond differently to the same pro- or anti- angiogenic factors [126]. This supports the 
idea of functional subtypes among endothelial cells. Endothelial cells can be immortalised; 
however, this may change their behaviour and response to stimuli [127]. Immortalised 
endothelial cells may alter their gene expression and physiological properties with repeated 
passaging in vitro, resulting in loss of vasculogenesis efficiency [127]. The non-endothelial 
cell types that support in vitro vascular network formation from endothelial cells (e.g. 
fibroblasts), may represent an undesirable cell type if the resultant culture is to be used for 
tissue engineering [100]. 
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5. Use of stem cells for in vitro vasculogenesis  
In recent years, stem cells have increasingly been used to develop vascular cultures; this is 
because stem cells have several advantages over terminally differentiated endothelial cells 
[19]. Stem cells are multipotent or pluripotent in nature, they show self-renewal, and their 
differentiation along various cell lineages can be manipulated by fine-tuning the culture 
conditions [19]. A few examples of the stem cells that can be used for endothelial, and 
ultimately vascular, differentiation are summarized in Table 3. Three main stem cell types 
used are: (i) embryonic stem cells (ESCs) [128], (ii) induced pluripotent stem cells (iPSCs) 
[129] and(iii) mesenchymal stem cells (MSCs) [130]. 
In addition, endothelial progenitor cells (EPCs), which originate in the bone marrow and 
contribute to the formation of new blood vessels in adults, are also useful in the study of in 
vitro vasculogenesis [125]. The differentiated endothelial cells arising from stem cells directly 
undergo vasculogenesis because of the presence of other cell types that have also 
differentiated from the stem cells.Alternatively, the endothelial cells can be isolated from 
the stem cell culture, without the unwanted additional cell types, and used for vascular 
morphogenesis (either in pure culture or co-culture with defined cell types) [113].  
One of the advantages of using ESCs is that they can differentiate into multiple vascular cell 
lineages simultaneously in culture. In principle, these different lineages can contribute to the 
newly-formed vessels (neovessels) in a way that closely resembles the in vivo vasculogenesis 
in early embryos [19, 131]. Endothelial differentiation and vascular morphogenesis in ESCs is 
controlled by culture conditions (such as the presence of growth factors in the medium and 
the use of feeder layers of stromal cells, or a substratum consisting of a natural or synthetic 
hydrogel [131, 132]). 
One approach to inducing the differentiation of ESCs in culture is to allow them to first 
aggregate into spherical cell masses, called embryoid bodies (EBs), in suspension 
culture[133]. The use of EBs as an intermediate step is common when ESCs are cultured for 
vascular differentiation (Table 3) [134]. In the absence of anti-differentiation factors (e.g. 
leukaemia inhibitory factor in mouse and feeder cell layer in human), ESCs differentiate into 
EBs consisting of mesodermal, ectodermal and endodermal lineages, similar to early 
embryogenesis [135]. In 2D (adherent) cultures the EB cells tend to proliferate and give rise 
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to undesired cell types such as fibroblasts [133]. By contrast, in 3D culture (suspension or 
gels), the proliferation of EB cells is limited, allowing greater control of the differentiation of 
the desired cell type [133]. Significant effects of different factors, such as culture substrate 
(collagen type-IV or fibronectin), cell seeding density, concentration of VEGF and FGF in 
medium, and culture duration, have been observed on the endothelial differentiation in 
human, mouse and zebrafish ESC culture [88, 136]. Similarly, TGF-β has been identified to 
induce vascular differentiation in human ESCs [137]. 









Main findings  Possible applications Ref. 
mESC EB static 3D Col-1 IMDM, EPO, 
VEGF, bFGF,  






mESC EB static 3D Matrigel® αMEM, 
VEGF 
Reporter proteins in vascular 





mESC Static 3D Col-1 IMDM, 
VEGF, bFGF  
EB formation and angiogenic 
sprouting. 
Drug screening [139] 
mESC Static 2D Gelatin  DMEM, 
VEGF 
Endothelial differentiation 






mESC EB static 2D Col-1 DMEM, 
VEGF 
VEGF receptors are involved 





mESC EB static 3D Col-1 IMDM, EPO, 
VEGF, bFGF 
Culture strategy, ECM 
substrate and growth factors 
effected vascular 
differentiation. 
Drug screening [142] 
hESC Static 2D Matrigel® EGM-2, 
BMP-4 

















miPSC EB static 3D Col-1 DMEM, 
VEGF 
TP73 gene regulates 
endothelial differentiation 
and vascular network 
formation. 
Cancer research [145] 
hiPSC Static 2D Fbn IMDM, 
VEGF, bFGF 










EGM and VEGF promoted 
endothelial differentiation 






Matrigel® EGM-2 Shear stress promoted 
endothelial differentiation 




hTMSC Static 3D Fibrin  EGM-2 TMSCs promoted and 
stabilized vessel formation 







Abbreviations: αMEM, alpha-minimal essential medium (Cellgro); bFGF, basic fibroblast growth factor; BMP-4, 
bone morphogenetic protein-4; Col-1, collagen type-I; DMEM, Dulbecco’s modified Eagle’s medium; EB, 
embryoid body intermediate; ECM, extracellular matrix; EGM, endothelial growth medium (Cambrex or 
Clonetics); EPO, erythropoietin; Fbn, fibronectin; Flow*, on the margins of the bottom of a flask on an orbital 
shaker; hAFSC, human amniotic fluid-derived stem cells; hESC, human embryonic stem cells; IMDM, Iscove’s 
modified Dulbecco’s medium; mESC, mouse embryonic stem cells; miPSC, mouse induced pluripotent stem 
cells; RSK, ribosomal S6 kinase; Static, static replacement culture; TP73, tumor protein-73; TTK, threonine and 
tyrosine kinase; VEGF, vascular endothelial growth factor. 
 
Another important stem cell type, similar to ESCs in pluripotency and differentiation events, 
is the iPSCs[149]. An advantage of iPSCs is that they can be generated by genetic 
reprogramming of any adult somatic cell population, and therefore raise fewer ethical 
concerns compared to ESCs [19]. Endothelial differentiation in iPSCs can be induced by 
applying similar methods used for differentiation of ESCs [150]. Furthermore, gene 
expression in endothelial cells derived from ESCs and iPSCs is very similar [150]. MSCs are 
multipotent stem cells residing in adult tissues; they have limited differentiation potential 
compared to ESCs and iPSCs[19]. Endothelial differentiation in human amniotic fluid derived 
MSCs has been shown to be inducible by VEGF [130]. MSCs derived from various tissues 
(bone marrow, hair follicle, adipose tissue and muscles) have been used for vascular 
regeneration studies reviewed in Ref. [19]. In some studies the MSCs have been reported to 
promote and stabilize vascular network formation from HUVECs (Table 2). 
In addition to the use of pluripotent and multipotent stem cells for endothelial 
differentiation and in vitro vasculogenesis, the unipotent EPCs also have the ability to 
differentiate into mature endothelial cells and form vascular tubes in culture [125]. The 
advantage of EPCs for culturing vascular networks is that these cells can be easily obtained 
from adult tissues such as peripheral blood [19].  In vitro studies have shown that the early 
EPCs do not directly undergo vascularization, but release factors to stimulate angiogenesis in 
distantly-cultured endothelial cells in a transwell[125]. Co-culture with MSCs has been 
proven to enhance vascular formation from EPCs both in vitro and after implantation in vivo 
[151, 152]. 
5.1. Issues and drawbacks with stem cell culture 
Although stem cell technology has several advantages for vascular engineering and 
regenerative therapy, there are some limitations to its use [19]. Thus, while ESCs have been 
extensively studied in laboratory animals such as mouse and rats, and stable cell lines have 
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been developed from these animals, the technique has been proven less successful for other 
species such as cattle, goat and dogs [149]. Furthermore, the very complexity of vascular 
differentiation from ESCs means that the growth factors necessary to support the generation 
and maintenance of multiple cell types need to be laboriously optimised [153]. Furthermore, 
the use of human ESCs for research raise ethical concerns [19]. 
ESCs and iPSCs are both pluripotent, and therefore it is challenging to direct the 
differentiation towards a specific lineage, and to obtain high quality pure cell cultures [149]. 
The iPSCs are developed by transfection of somatic cells with pluripotency genes; however, 
the efficiency of the process is very low (less than 1%) [154]. The iPSCs (in contrast to ESCs) 
are derived from adult differentiated cells by de-differentiation. Then, if re-differentiated 
into a specific cell type, they attain some of the characteristics of that cell type but are not 
identical to their normal counterparts [154]. Other issues with stem cells is that the isolation 
of MSCs from adult tissues requires invasive surgical procedures, and only yields small 
numbers of cells; the proliferation of these cells is also limited in vitro[155]. Furthermore, 
the MSCs isolated from different tissues or life stages are not the same, and therefore have 
different culture requirements and angiogenic potentials [156]. 
The isolation and culture methods for EPCs are only relatively recently developed (Asaharaet 
al., 1997 [157]). For this reason, there is no standard protocol among researchers. It should 
be noted that there are no specific markers for EPCs because many of the genes expressed 
by EPCs are also expressed in hematopoietic progenitors [158]. Similar to the iPSCs and 
MSCs, the number of EPCs found in isolated adult tissue cells is very low, and this greatly 
limits their study [19]. Finally, analysis of EPCs in long-term culture has shown that the late 
passage cells (45 days after the initiation of the primary culture) have changed morphology, 
reduced their proliferation rate, show high β-galactosidase expression and loss of vascular 
network formation ability, compared to the early passaged cells [159]. 
6. Use of tissue explants for in vitro angiogenesis  
An important strategy for vascular morphogenesis in vitrois to stimulate the growth of the 
blood vessels existing in isolated sections or fragments of specific tissues[127].The 
development of a well-defined blood vascular network requires the incorporation of 
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multiple cell types both in vivo and in vitro, as discussed in the previous sections. The use of 
tissue explants is important in this context, because these explants already contain multiple 
cell types, and the angiogenesis stimulated in these cultures closely represents the 
corresponding process in vivo[127].Furthermore, tissue explant experiments are relatively 
easy to perform and allow a large number of cultures to be derived from a single tissue 
sample[160].  
Various tissue explants have been shown to have the ability to develop vascular sprouts in 
vitro (Table 4). Examples include cross sections of aorta called aortic rings [161]; metatarsal 
bones [162]; retina fragments [163]; choroid-sclera fragments [164]; and adipose tissue 
[165]. In most cases, the tissues for explant preparation are isolated from developing rodent 
embryos or neonates. Tissue explants from other species such as chick embryo aortic arch 
[166], rabbit aorta [167] and pig carotid artery [168] have also been adapted for sprouting 
angiogenesis. Furthermore, angiogenic sprouting has also been reported from human tissue 
explants e.g. adipose tissue [165], aortic explants from aborted embryos [169], placental 
explants [170, 171] and umbilical artery rings [172]. 
Explant cultures are usually established in a 3D gel matrix in the presence of angiogenic 
growth factors, and are examined for microvessel outgrowth (vascular sprouting)[127, 173]. 
The aortic ring model from various species is the most commonly used explant for studying 
in vitro angiogenesis (Table 4). The stimulatory effect of various factors, such as angiogenic 
growth factors (especially VEGF) and ECM components, on the growth of vascular sprouts 
from aortic ring have been extensively studied, reviewed in Ref. [174]. Recentlydeveloped 
explant cultures, using fetal metatarsals from mice, have shown advantages over the aortic 
ring model, in that they do not require a 3D matrix and exogenous growth factors for 
vascular sprouting [162].In general, explant cultures can serve as an intermediate between 
the endothelial cell culture on the one hand, and in vivo models on the other. They are also 
thought to be more reliable for studying the mechanisms of angiogenesis andtesting the role 
of regulatory factors [175]. 
6.1. Limitations of explant cultures 
Besides the advantages of explant cultures, certain limitations need to be addressed before 
the technique can be fully accepted for research in tissue engineering and regenerative 
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medicine. The mouse aortic ring model shows significant variability in microvessel sprouting 
from explants isolated from different age and strain of animals [176]. Variability in outcome 
has also been reported using explants isolated from different vessel types (artery or vein) of 
the same individual animal [177]. The vascular sprouts in the aortic ring model regress over 
time in culture (with peak sprouting between days 6 and 7), and this limits the analysis time 
and increases variability in results with culture duration [161]. Furthermore, the aortic rings 
are derived from large vessels, and therefore do not truly represent in vivo angiogenesis, 
which is a microvascular process [127]. 









Main findings  Possible 
applications  
Ref. 
mAR Static 3D Col-1 Opti-MEM, 
VEGF 
VEGF and collagen 
increased vessel sprouting. 
Drug screening [161] 
mAR Static 3D Col-1 MCDB131, 
VEGF  
Age of the mouse inversely 
affected vascular sprouting 
from explant. 
Drug screening [178] 
mAR Static 3D Col-1 ESFM Endostatin inhibited 
vascular sprouting by 
modulating endothelial 
cell-ECM interaction. 
Cancer research [179] 
rAR Static 3D Matrigel® EGM-200 Ascorbate inhibited 
sprouting angiogenesis.  
Cancer research [180] 
hUAR Static 3D BME EGM-2 Capillary spouting upon 
VEGF stimulation. 
Cancer research, 
drug screening  
[172] 
cAA Static 2D Matrige® bFGF, VEGF Chemical compound 





mAT static 3D Col-1 MCDB131, 
VEGF  
Angiogenic sprouting. Drug screening [182] 






drug screening  
[165] 
mRE Static 2D PTFE DMEM, 
VEGF 
VEGF stimulated vascular 
sprouting. 
Drug screening [183] 
mRE Static 3D Fibrin  DMEM, 
VEGF 
VEGF stimulated sprouting 
angiogenesis in a dose 
dependent manner. 
Drug screening [184] 
mMT Static 2D Gelatin OR 
col-1 
αMEM Vascular sprouting 
occurred without 





mMT Static 2D  αMEM, 
VEGF 
VEGF recovered the 
impaired vascular 





mPE Static 2D Col-1 M199, VEGF, 
bFGF 








Abbreviations: αMEM, alpha-minimal essential medium; bFGF, basic fibroblast growth factor; BME, basement 
membrane extract (BD Biosciences); cAA, chick aortic arch; Col-1, collagen type-I; DMEM, Dulbecco’s modified 
Eagle’s medium; EBM, endothelial basal medium (Lonza); ECM, extracellular matrix; EGM-MV, endothelial 
growth medium microvascular; EGM, endothelial growth medium (Cascade Biologics); ESFM, endothelial 
serum-free medium (Life Technologies); hAT, human adipose tissue explant; hUAR, human umbilical arterial 
ring; M199, medium 199 (Gibco); mAR, mouse aortic ring; mAT, mouse adipose tissue explant; MCDB131, basal 
medium (Invitrogen); mMT, mouse metatarsal explant; mPE, mouse proepicardium explant; mRE, mouse 
retinal explant; Opti-MEM, minimal essential reduced-serum medium (Gibco); PTFE, polytetrafluroethylene 
membrane; rAR, rat aortic ring; Static, static replacement culture; VEGF, vascular endothelial growth factor. 
Tissues containing microvascular networks (e.g. adipose tissue and retina) can be used for 
explant preparation. However, these tissues are more difficult to isolate and, like the aortic 
explant, show variability between experiments [163]. The high levels of capillary sprouting 
observed in adipose tissue explant cultures are in many senses an advantage; however they 
do make it difficult to identify all the sprouts individually and interpret the results [165]. 
Similarly, angiogenic sprouts from fetal mouse metatarsal explants present microvascular 
features; however, their isolation and culture procedures also require advanced technical 
skills, which are key to the reproducibility of the research[162]. Finally, the metatarsal and 
chick aortic arch explants are isolated from developing embryos and have high proliferative 
capacity; therefore, angiogenesis in these models does not represent the in vivo situation in 
adults [127]. 
7. Zebrafish: a new model species for studying in vivo 
vasculogenesis and angiogenesis 
The zebrafish is a freshwater teleost fish [187] that is emerging as a model of choice for 
studying vasculogenesis and angiogenesis[188]. The embryos and larvae are often used in 
these studies because of their external fertilization, optical transparency at early stages, and 
the ease of exposure to test substances (by simply adding the compound to the swimming 
water) [189]. Furthermore, the genome comparison study has revealed that there is at least 
one orthologue in zebrafish genome for more than 70% of human protein coding genes [31]. 
Vascular development and function in zebrafish are relatively conserved, compared to the 
same processes in other vertebrates [188]. 
The embryos develop a simple vascular system with circulating blood as early as 24 hours 
post fertilization (hpf) [37]. Vascular development can be directly observed non-invasively in 
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the living, transparent embryo [28]. Enhanced visualization of vascular development can be 
achieved by injecting fluorescent micro particles into the blood stream, or by using 
transgenic lines such as kdrl:GFP and fli:GFPthat express green fluorescent protein (GFP) in 
vascular cells [28].  
For these and other reasons, vascular development in zebrafish — from early differentiation 
of angioblasts to the maturation of blood vessels—has been extensively studied [32, 37, 190, 
191]. Studies have shown similar angiogenic responses to the test substance irisin, in 
zebrafish embryos in vivo, and in HUVECs in vitro[192]. In another example, the genetic 
mutation (gridlock), which causes aortic malformations and congenital heart defects in 
humans, showed similar phenotypic effects in zebrafish [193]. Zebrafish have been 
successfully utilized to model several human vascular diseases reviewed in Ref.[32].  
Similarly, a zebrafish in vivo xenograft model has been developed to study human 
carcinomas [194]. These studies have shown successful invasion, metastasis and 
extravasation of various human tumorcells in zebrafish embryos and adults [194]. It has 
been demonstrated that the transplantation of human WM-266-4 melanoma cells and 
breast adenocarcinoma cells in zebrafish embryos induced angiogenesis in the host 
vasculature; this led to the formation and infiltration of neovessels into the tumor 
masses[195, 196].Other examples of human carcinomas studied in zebrafish include breast 
cancer bone metastasis [197], uveal melanoma [198] and retinoblastoma [199].  
The zebrafish possesses remarkable regenerative capacity in several organs (including the 
caudal fin and heart [200, 201]) which makes it a useful model for studying regeneration 
[202]. The regeneration of organs also involves the regeneration of blood vessels, and 
therefore the regenerative capacity of zebrafish is also important for vascular regeneration 
studies [28]. 
7.1. Zebrafish transgenic reporter lines for vascular studies 
Several transgenic lines have been developed for zebrafish which express fluorescent 
proteins under vascular cell specific promoters [28]. These transgenic lines allow the tracking 
of the differentiation, proliferation and migration of individual cells during vascular 
developmentin vivo and in vitro [28]. Moreover, different transgenes can be combined in the 
same embryo,as was done with a line (scl-PAC:GFP) expressing fluorescent proteins in both 
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endothelial and blood cells; that line permitted the observation of the development of the 
vascular system and blood flow simultaneously [203]. 
The most important transgenic line that we are utilizing to study vascular development in 
zebrafish is the kdrl:GFP line (Figure 3A). This transgenic line isalso known as Tg(kdr:eGFP) or 
Tg(flk1:eGFP) [204]. In this line, GFP is specifically expressed in endothelial cells under the 
control of the VEGFR2 or kdr-like gene [204]. The kdrl:GFP line allows high resolution analysis 
of single cell migration and vascular development in living embryos [204].The utility of 
kdrl:GFP zebrafish embryos has been confirmed as a high-throughput model for screening 
the effect of toxic compounds on vascular development[205].  
Other transgenic zebrafish lines are available for vascular studies, although they have some 
limitations. For example, In Tg(Tie2:eGFP) the GFP expression is relatively weak in the 
vascular cells[206]. Similarly, in Tg(fli1:eGFP) the GFP is expressed in certain non-vascular 
cells which interferes with the results especially in the head region of the embryo [204]. 
Furthermore, studies on Tg(fli1:eGFP) have shown changes in the gene expression of a 
number of genes, compared to the wild type embryos, which may affect the results while 
using transgenic zebrafish for experiments [207]. 
In summary, zebrafish is a high-throughput, easily quantifiable, fast developing and relatively 
inexpensive in vivo model for vascular studies. However, there are some drawbacks 
associated with this model. For example, the relevance of zebrafish embryo model to 
understand human angiogenesis is questioned, as there is a large evolutionary time 
difference between the two species [175]. Therefore, preclinical drug screening in zebrafish 
should always be followed by validation in mammalian models beforegoing to clinical trials 
[28]. 
8. Future prospects for using zebrafish cells for in vitro 
vasculogenesis and angiogenesis 
In principle, many of the techniques discussed in the previous sections for in 
vitrovasculogenesis and angiogenesis (using mammalian endothelial cells, ESCs and tissue 
explants), can also be adapted for use in the zebrafish model. With the availability of primary 
embryonic cells due to high fecundity of the species, and easy cell isolation procedures, the 
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drawbacks associated with adapted cell lines can be avoided [208]. In addition to the above 
mentioned characteristics, zebrafish also possess specific desirable features for in vitro 
applications. 
8.1. Cell culture techniques in zebrafish 
The external fertilization andlarge number of fast developing embryos, allow easy harvesting 
of large numbers of cells and quantities of tissues from different developmental stages[209]. 
Zebrafish cells grow at a lower temperature (26-28 °C) than chick and mouse cells and do not 
usually require a CO2-enriched atmosphere [209]. These properties allow zebrafish cells to 
be grownat room temperature, although the use of a simple incubator is recommended to 
help maintain sterile conditions[209]. The protective covering of the chorion, which is 
present until hatching at around 48 hpf, partly isolates the embryos from the 
environment[210]. This is important for in vitro studies because it maintains the embryos in 
an aseptic condition[211]. 
To harvest sterile cells or tissues from zebrafish embryos it is necessary to decontaminate 
the surface of the chorion. Using this approach, it is possible to isolate and culture sterile 
cells from blastula (3 hpf) or gastrula (24 hpf) stage embryos [209, 212].In a recent study, we 
have shown that embryos with a chorion decontaminated at 24 hpf could be further 
cultured to 5 dpfunder aseptic conditions [173]. The tissues and cells isolated from these 
embryos were successfully maintained free of contamination for eight days in culture.  
8.2. Zebrafish embryonic stem cells 
As is the case with mouse and human ESCs, it is possible to maintain zebrafish ESCs in a 
pluripotent state inlong-term culture[213].In zebrafish and medaka, the ESCs can be derived 
from the embryo before the blastocyst stage; these cells may possess a higher degree of 
pluripotency (and even totipotency), compared to mammalian ESCs derived from 
blastocysts[214].When differentiation inhibition factors are depleted in the culture medium, 
the zebrafish ESCs have the ability to undergo differentiation into a range of specialized cell 
types [212].The spontaneous differentiation of zebrafish ESCs into neuron-like cells, muscle-
like cells, embryonic carcinoma-like cells and fibroblast-like cellshas been demonstrated 
[209, 212, 215]. However, little is known about the condition needed to induce specific 




   
Figure 3: Confocal images of transgenic zebrafish kdrl:GFP whole embryo (A) and EB culture (B-D). (A) A 5 dpf 
kdrl:GFP embryo showing florescent endothelial cells forming blood vessels. Scale bar, 200 µm. (B, C and D) 
Developing embryoid body on subsequent days of culture (day 1, day 6 and day 8, respectively) on a mixture of 
collagen type-I, Geltrex™ and fibrin substratum, showing the development of vascular network-like structures 
from kdrl:GFP+ endothelial cells. Scale bars, 100 µm. 
 
The induction of myogenic differentiation in zebrafish primary ESCs has been shown by 
culturing these cells on a laminin substratum, in medium containing insulin [216], FGF [217] 
or sonic hedgehog protein [218]. In another study, the seeding density (between 1 and 2 × 
104 cells/cm2) of zebrafish primary ESCs, co-culture with a zebrafish fibroblast-like cell line 
(ZF4) and medium supplementation with insulin, were found to induce cardiomyocyte 
differentiation [219]. Similarly, an increase in the generation of primordial germ 
cellresembling-cells was found in zebrafish blastocyst cell cultures after the addition of BMP-
4, EGF and retinoic acid to the medium [220]. Furthermore, the use of FGF and VEGF have 
been shown to increase differentiation towards the endothelial cell lineage in zebrafish 
blastocyst cells [221]. 
Zebrafish blastocyst cells aggregate into EBs in culture. We have shown that the percentage 
of endothelial-like (kdrl:GFP+) cells in EBs is increased by culturing them in suspension (i.e. 
hanging drop culture)rather than in adherent culture, and by adding endothelial growth 
supplements, including VEGF, to the medium [136]. We found that the kdrl:GFP+ cells in EB 
culturesform vascular network-like structures on hydrogel substrates (Figure 3B-D). 
A 
B C D 
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8.3. Cultures of specialised zebrafish cell types 
Attempts have been made to develop cultures of specialised cell types using progenitor cells 
isolated from zebrafish embryos.In one study, neural crest cells, isolated from dissociated 14 
hpf (10-somite stage) embryos, were maintained in culture [222]. These cells were shown to 
proliferate, migrate and differentiate into neurons, chondrocytes and glial cells in vitro[222]. 
Strategies have also been described for the culture of primary neurons from developing 
brain and spinal cord cells of zebrafish embryos [223]. We have found that the endothelial 
cells in dissociated hearts, isolated from 5 dpf zebrafish embryos,form colonies ona 
fibronectin substratum; however, these cultures could only be maintained for short periods, 
possibly because of low seeding-density [173]. 
These studies suggest that zebrafish embryonic cell culture can be an important model for 
studying endothelial differentiation and vascular morphogenesis in vitro. In principle, it could 
be possible to use zebrafish kdrl:GFP embryos for the isolation of endothelial cells using 
fluorescence activated cell sorting (FACS). The development of these cells into vascular 
networks in response to various signals could then be readily tracked in live cultures without 
the need to fix and stain them. Furthermore, tissues and organ explants from zebrafish 
embryos can be a promising model for sprouting angiogenesis, as we have shown using liver 
and heart explants from 5 dpf embryos [173]. 
In summary, the zebrafish allows easy access to large numbers of primary cells, and vascular 
development in cultures derived from these cells occurs in a complex environment of other 
cell types. In contrast, it is difficult to access primary cells and tissues in mammalian models, 
and the vascular culture using endothelial cell lines such as HUVECs does not reflect the 
complex process in vivo. 
8.4. Disadvantages of zebrafish in vitro model 
Zebrafish embryonic cell cultures usually combine cells or tissues from a large number of 
individuals due to the small size of embryos [216]. As a result, the cell population obtained is 
genetically heterogeneous, and may not be ideal for gene expression analysis [216]. Despite 
the simplicity of the required culture conditions (i.e. low incubation temperature and no 
requirement for a CO2-enriched atmosphere), studies have shown that zebrafish primary 
embryonic cells require a complex medium containing FGF and fish embryo extract for their 
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growth [213]. The lower incubation temperature for zebrafish cells may not be ideal for 
human cells if a co-culture has to be established. 
The zebrafish embryonic cells usually have to be cultured on a feeder layer of growth-
arrested cells to maintain their pluripotency [211]. The development of vascular network in 
primary zebrafish embryonic cells and tissues in the presence of other supporting cell types 
may be considered as an advantage as it closely mimic the in vivo situation. However, this 
provides less control over the in vitro vascular development compared to endothelial cell 
lines. Furthermore, because the zebrafish is a relatively new research model, the 
differentiation and culture conditions for its cells still needs to be optimised. 
9. Organoids: un-vascularized organotypic cultures 
A remarkable capacity for self-organization in vitro is shown by stem cells (embryonic or 
adult pluripotent stem cells) and primary tissues (organ explants or dissociated cells). This 
capacity allows them to develop into ‘organoids’ — 3D cell masseswith organ-like 
properties[224]. In an organoid, multiple organ-specific cell types are arranged together, 
recapitulating some properties (structural and functional) of an organ [225]. The ability to 
control the differentiation in pluripotent stem cells makes them a model of choice for 
organoid cultures[226]. Using these cells, organoids of a number of organs including brain, 
retina, stomach, intestine, lungs, liver and pancreas, have been developed (reviewed in Ref. 
[12]).The organoid culture not only allowsthe study of developmental processes,it also 
represents an emerging model system to study diseases, to screen toxicants, and to develop 
personalized and regenerative medicine[12, 226]. 
These and other studies suggest organoids might be a good starting point in the effort to 
develop more complex organ cultures. However, certain limitations of organoid cultures 
need to be overcome. First, because the cells in an organoid show self-organization, the 
degree of experiment control over organoid organization is limited; this means 
thatindividual organoids within the same culture may show cellular heterogeneity[227]. This 
affects the reproducibility of the results [227].Second, some tissues, such as neural tube and 
brain,are not easy to establish in 3D culture, although successes are increasingly being 
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reported [228]. Finally, the simultaneous effect of growth factors and extracellular matrix in 
these cultures may inhibit some pathways required for organogenesis [229]. 
The major issue with organoids, as with other tissue engineering approaches,is the lack of 
vascularization. This necessarily means that organoids are diffusion-limited and cannot fully 
develop into mature organs in vitro[228]. One study demonstrated the development of 3D 
neural organoid constructs with a vascular network inside, by co-culturing neural progenitor 
cells, endothelial cells, MSCs and macrophage precursors [230]. A similar neurovascular 
spheroid model has been developed using primary cortical tissue cells isolated from 1-3 days 
postnatal mice and rats [231]. In another study theintestinal organoids developed from 
human ESCs were implanted in mice under the kidney capsule[232]. These organoids further 
expanded, maturated and demonstrated intestinal morphology and function after 
vascularization by the host vasculature[232].  
Taking it a step further, the use of decellularized whole organs as scaffolds for culturing bio-
artificial organs are now gaining interest. In this technique the cell population of an organ is 
removed by perfusion with detergents or by mechanical means, while retaining the original  
three dimensional shape of the extracellular matrix[233]. These organ scaffolds are then 
repopulated with stem cells, endothelial cells or a mixture of specific cell types (depending 
on which organ was used) to generate an organ culture [233]. Using this strategy Ottet al. 
have developed a heart construct using decellularized rat heart seeded with cardiac or 
endothelial cells [234]. The recellularized construct retained the physiological structure of 
the heart and showed contractions, pump function and response to drugs [234].Similarly, 
decellularized rat intestine becomes vascularized when human endothelial cells are seeded 
into its empty vascular channels[235]. 
10. Beyond organoids: microfluidics and the development of a 
functional vascular network 
In this final section we want to look at some future prospects in the field of in vitro vascular 
networks. These networks will always remain of limited value unless they support a 
functional blood flow. In a living animal, this flow is powered by the heart. But how can 
blood flow be initiated and maintained in a culture system? One obvious answer is to use 
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microfluidic technologies to pump blood or some nutrient liquid through the vascular 
network. 
Microfluidic systems give control over the biophysical and biochemical microenvironment of 
cells, allowing the analysis of complex interactions between different cell types and the 
respective signalling molecules [236].Microfluidic devices(chips) are made from various 
material (including glass and poly dimethyl-siloxane), using microfabrication techniques. 
They contain hollow channels that can be filled with ECM components and medium [13]. The 
devices can simply be connected to a medium reservoir to generate a passive flow through 
the channels; or to a pump for more constant flow rate (Table 5).Using unique combinations 
of materials (with different structural and mechanical properties), microfabrication 
techniques, ECM components, growth factors, cell types and flow rates, a controlled 
environment can be created to promote vascular development [236]. 
These properties of microfluidic systemsmight, in the future, be adaptable to the 
vascularisation of organoids in vitro. This, in turn, could allow more advanced development, 
by providing chemical cues and nutrient/waste exchange through a perfusable vascular bed. 
Connecting an organoid culture to a microfluidic vascular bed would also allow the required 
changes in gene expression in response to the shear stress generated by the flow of 
medium.  
Microfluidicscould also make it possible to manipulate the course of organogenesis in 
organoid cultures. For example, the flow rate could be increased with time to fulfil the 
increasing nutrient requirements of the growing tissue. Designing a microfluidic device with 
multiple channels connected to different parts of the culture chamber, could also allow the 
delivery of a specific growth factor to aspecific region of the developing organ. Furthermore, 
a microfluidic vascularized organ culture would make it possible to visualize the core of 
optically dense tissues by introducing staining solutions through the vasculature. 
10.1. Examples of microfluidic vascular culture systems 
The microfluidic systems designed for culturing vascular networks are summarized in Table 5 
and Figure 4. In one example of vascular culture in a microfluidic system, HUVECs and 
human lung fibroblasts were co-cultured in a perfused 3D fibrin gel [237]. Thenetworks that 
developed allowed the transport of nutrients, molecules and cells, and also showed 
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physiological responses to flow-induced shear stress [237]. The flow rate in this experiment 
was 5 µL/min, which generated a shear stress of 0.31 - 7.22 dyne/cm2. This value is close to 
the physiological level of shear stress (1 to 10 dyne/cm2) [237]. It should be noted that the 
shear stress generated by a particular flow rate depends on the dimensions of the 
microfluidic channels. In the same microfluidic device the authors showed that the presence 
of flow (regardless of flow direction) facilitates vasculogenesis by HUVECs, and that 
angiogenic sprouting occurs only in the direction opposite to the flow direction[238]. 
Similarly, angiogenic sprouting in 3D collagen type-I gel from HUVEC cultures in a 
microfluidic device showed morphological features resembling in vivo angiogenesis [239]. 
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Abbreviations and symbols:Active, flow is generated by a pump with constant flow rate; PDL, poly-D-lysine; AEC, 
alveolar epithelial cells; Ang-1, angiopoietin-1; bFGF, basic fibroblast growth factor; CC, cancer cells (colorectal, 
breast or melanoma cell line); Col-1, collagen type-I; EBM, endothelial basal medium; ECFC-EC, human 
endothelial colony forming cell-derived endothelial cells;ECGS, endothelial cell growth supplement;EGM, 
endothelial growth medium; EGM-2MV, endothelial growth medium microvascular;Fbn, fibronectin;HBMSC, 
human bone marrow-derived mesenchymal stem cells; HBMVEC, human brain-derived microvascular endothelial 
cells;HBVP, human brain vascular pericytes;hiPSC-CN, humaninduced pluripotent stem cell-derived cortical 
neurons; HMVEC, human dermal microvascular endothelial cells; HPMEC, human pulmonary microvascular 
endothelial cells;HPP, human placental pericytes; HUVEC, human umbilical vein endothelial cells; iPSC-EC, human 
induced pluripotent stem cells-derived endothelial cells;M199, medium 199 (Lonza); NHLF, human normal lung 
fibroblasts; OB, osteoblasts; Passive, the flow is generated by hydrostatic pressure of the medium in a reservoir; 
PEG, polyethylene glycol hydrogel;POMaC, poly(octamethylene maleate (anhydride) citrate); RBME, rat brain 
microvascular endothelial cells; RCC, E-18 rat cortical cells; TNF-α, tumor necrosis factor alpha; VEGF, vascular 
endothelial growth factor; VVM, VascuLife® VEGF medium; ZBC-EB, zebrafish blastocyst cell-derived embryoid 
bodies; *, see Figure 4 for further description of device design; **, flow velocity calculated by tracking the 
movement of fluorescent dextran particles through the network. 
 
These studies employed a commonly-used microfluidic design containing a middle channel 
filled with ECM, and interconnected with two side channels which conduct the medium flow 
(Figure 4A).In this device the vascular network is connected to the media channels through 
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the lumen openings[241]. This allows the vascular network to be perfused by chemical 
compounds or cells. The device allows rapid quantification of changes in vascular networks 
in response to test compounds[241].Using the same design, Jeon et al. have shown the 
extravasation of cancer cells, introduced through the perfused vascular network, into the 
surrounding bone-mimicking matrix [240]. In a similar device, human colorectal or breast 
cancer cells co-cultured with endothelial cellsin 3D ECM in the middle channel have been 
shown to develop into vascularizedtumor aggregates[243]. These tumor-like structures 
showed reduced growth, and sometimes even regression occurred,in response to standard 
vascular targeting therapies infused via the microvessels[243]. 
Based on a similar principle, Moya et al.[246] designed a chambered central channel with 
each chamber connected to the two microfluidic channels on either side through a 30 µm 
pore (Figure 4B). In that study the authors demonstrated that the endothelial cells, co-
cultured with fibroblasts in 3D fibrin matrix in the central chambers, self-assembled into an 
interconnected capillary network,that anastomosed on each side to the channels (Table 5). 
This device allows the culture of multiple, vascularized microtissues which were nearly 
identical between the different chambers[253]. The geometry of microfluidic channels and 
media reservoirs in this device, allow better control over the flow distribution in each 
chamber to generate near physiological shear stress [253]. Furthermore, these channels also 
allowed the transport of chemical signals from one culture chamber to the other [247].Using 
a modified version of this device, with an extended central chamber connected by multiple 
pores to the side channels, Hsu et al.have shown that interstitial flow and hypoxia can 
independently stimulate vasculogenesis [254].  
Another device (Figure 4C) mimics the alveolar capillary interface by allowing the culture of 
human pulmonary microvascular endothelial cells on one side, and alveolar epithelial cells 
on the other, of a porous membrane inside a microfluidic channel[250]. This device allows 
the transport of chemical signals from one compartment to the other on stimulation [250]. 
This technique can be applied to develop other organ models (such as intestine, kidney, liver 
and blood-brain barrier), by culturing the corresponding cells in the device [255].An 
alternative approach is the pre-moulded hollow network (Figure 4D) in a 3D collagen type-I 
matrixwith embedded supporting cells (in this case, human brain vascular pericytes)[248].In 
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that study, the HUVECswere seeded into the cavities of cast, which first formed a lining to 





Figure 4. Microfluidic devices commonly used for culturing vascular-like networks. (A) 
Three channel microfluidic device [238, 240]. The middle channel (m) is filled with 
extracellular matrix with embedded cells. The two side channels (s) conduct the medium 
flow (arrows). (B) Device with a central culture chamber connected to two channels on 
either side [246]. Endothelial cells embedded in 3D matrix in the central chamber self-
organize into a network, allowing medium perfusion from one channel to the other. (C) 
Microfluidic device mimicking capillary-tissue interface with endothelial cells on one side 
and epithelial cells on other side of a porous membrane [250]. The medium flow (arrows) 
can be established on the endothelial side only, or on both sides. (D) In this device, 
endothelial cells line the built-in channels cut into a hydrogel with embedded supporting 
cells [248, 249]. (E) A microfluidic channel slide with a 3D matrix plug (P) in the middle of 
the channel [173]. The medium flows on either side of the plug (a small amount may 
penetrate the gel by diffusion). Note that (B and D) comes closest to a growing vascular 
bed connected to the microfluidic system. Arrows showing the direction of the medium 
flow. For further discussion of microfluidic devices in the field of vascular culture, see 
Refs. [13, 99, 256]. 
 
In a similar device, a perfused vasculature has been developed by seeding HUVECs inside 
moulded channels in a synthetic scaffold [249]. The network thus formed was able to 
vascularize cardiac and hepatic tissues cultured on the outside of the scaffold. The material 
used for the scaffold in that study waspoly(octamethylene maleate (anhydride) citrate) 
(POMaC;a biodegrade-able and biocompatible scaffold) [249]. In that setup, the micro pores 
A B 
C 






incorporated into the scaffold allowed the uptake of nutrients, chemical compounds and 
cells from the vessels, and the release of metabolites into the vessels by the surrounding 
tissue [249].By increasing the flow rate (from 0.7 to 8.0 µL/min) across the lifespan of the 
culture, this device allowed the growth of tissues of up to 2 mm thickness. 
In most of the cases discussed above, endothelial cell lines are used to culturevascular 
networksin a microfluidic system. The stem cells and explant cultures have been very little 
used in such studies. We have shown that zebrafish EBs embedded in a 3D matrix(mixed 
collagen type-I, Geltrex™ and fibrin gel components),formed longer and wider vascular 
sprouts when cultured in a microfluidic channel (Figure 4E) compared to the conventional 
(static) 96-well plates[173]. 
10.2. Technical challenges for the future 
As we have discussed above, scientists are getting closer to reaching the goal of a functional 
vascular network perfused by microfluidics in vitro. However, there are some severe 
technical challengesto be overcome. Presumably, some kind of synthetic interface or 
connector will be needed to connect the living vessels with microfluidic system. Another 
major challenge will be to maintain an increasing blood flow as the tissue explant, attached 
to the vascular network, grows in size. Thus, the growing tissue will require vessels of 
increasing diameter, and this in turn will require an expanding connection to the microfluidic 
system. Solutions to these problems will require intensive research.  
11. Conclusions 
In summary, the techniques developed for in vitrovascular network formation in mammals 
are producing rapid advances in our understanding. They can also be applied to zebrafish 
cells and tissues. For its benefits such as easy access to primary embryonic cells,availability 
of transgenic lines to visualize endothelial cells andconserved molecular pathways, the 
zebrafish can be a significant first-step model for studying in vitro vascular development. 
Lack of a functional vascular system is currently the major limitation to take the organoid 
technology a step further to develop whole organ culture.In recent years, microfluidic 
technology have shown great advances in developing in vitroperfused vascular networks. 
Ultimately, the future of tissue culture and organ culture will be greatly extended if a 
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functional vascular network can be developed, that have the ability to transport the required 
factors for the growth and to remove metabolites of the tissues in vitro. The major 
challenges in establishing such a system,that the future studies must overcome, would be to 
recapitulate the key features of vascular system such as barrier function and vasoactivity, 
besides weather or not the vascular network is perfusable. Further research will be required 
to develop a microfluidic system in which there is a remodelling of the vascular-to-hardware 
connection, as would be essential in order to meet the increasing demands of the growing 
tissue. 
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